Immunogenicity of Influenza Vaccinations
A legfontosabb adatok
- Ki végzi
- Duke University
- Hol
- Atlanta, Cleveland, Phoenix, Pittsburgh, St Louis és Tempe (Egyesült Államok)Mind a 7 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 4. fázis
- Résztvevők
- 606 fő vett részt
- Kezdés
- 2024. szept. 9.
- Befejezés
- 2025. jún. 4.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Flucelvax® (ccIIV3)
- Flublok® (RIV3)
- A regiszteradat frissítve
- 2026. július 28.
Ki vehet részt
- Életkor
- 18 év – 64 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Adults aged 18-64 years that have not received the current season's influenza vaccine
- English literate
- Email or text message capability for weekly follow-up
- Intention of receiving influenza vaccine based on ACIP-CDC guidelines
- Willing to provide written/electronic informed consent
- Intention of being available for entire study period and able to complete all relevant study procedures, including follow-up phone calls and clinic visits
Ki nem vehet részt
- Receipt of the current season's influenza vaccine (receipt after July 1, 2024)
- History of severe allergic reaction after a previous dose of any influenza vaccine or to an influenza vaccine component
- Receipt of any licensed or investigational live vaccine within 6 weeks or non-live vaccine within 2 weeks prior to enrollment in this study or planning receipt of any vaccines between visits 1 and 2 of the study (approximately within 4 weeks after the receipt of study-administered vaccine)
- History of febrile illness (> 100.0°F or 37.8°C) within the past 72 hours prior to vaccine administration
- History of Guillain-Barré syndrome
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
- Any condition which, in the opinion of the investigators, may pose a health risk to the participant or interfere with the evaluation of the study objectives; Temporary Delay Criteria (Visit 1)
- Currently pregnant, planning to become pregnant within the first three months of the study per participant self-report
Helyszínek itt: Egyesült Államok
- Centers for Disease Control and PreventionAtlanta, Egyesült Államok
- University Hospitals Cleveland Medical Center*Cleveland, Egyesült Államok
- VA Northeast Ohio Healthcare System (VANEOHS)Cleveland, Egyesült Államok
- Valleywise Health Comprehensive Health CenterPhoenix, Egyesült Államok
- Department of Family Medicine, University of Pittsburgh School of MedicinePittsburgh, Egyesült Államok
- Washington University IDCRUSt Louis, Egyesült Államok
- ASU Biodesign InstituteTempe, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is a randomized immunogenicity study in an enrolled cohort with active surveillance for influenza-like illness (ILI). During this study, participants will be randomly assigned to receive an approved cell culture-based influenza vaccine (Flucelvax®) versus a licensed comparator influenza vaccine (Flublok®). Blood samples from participants will be collected for measurement of biomarkers of immune response at baseline (visit 1; day 1), post-vaccination (visit 2; day 29), and post-season (visit 3; day 181). Participants will be asked if they wish to also provide saliva specimens at baseline (visit 1; day 1), post-vaccination (visit 2; day 29), and post-season (visit 3; day 181). Serum and peripheral blood mononuclear cells (PBMC) and plasma samples will be isolated from whole blood and tested for biomarkers of vaccine immunogenicity, and duration of antibody responses.
A teljes eredeti leírásKevesebb
Participants will receive electronic surveys via email or text message weekly asking about changes in health status and new ILI symptoms; those reporting illness may be asked to provide a respiratory swab for laboratory testing for influenza and other respiratory viruses and up to 2 additional blood draws (acute [<10 days after symptom onset] and convalescent [28 days after acute visit if lab-confirmed positive for influenza]).
A vizsgálat 2 csoportja
- Flucelvax® (ccIIV3)A vizsgált kezelés
Participants will receive Flucelvax® (ccIIV3) at Visit 1.
- Flublok® (RIV3)A vizsgált kezelés
Participants will receive Flublok® (RIV3) at Visit 1.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Measuring Immunity Against Circulating Influenza Viruses: Randomized Immunogenicity Study Among US Adults Aged 18-64 Years Comparing Two Approved Influenza Vaccines
- Publikációk
- Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025.medRxiv : the preprint server for health sciences, 2026
- A regiszteradat frissítve
- 2026. július 28.